Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $1.2 billion.

  • IDEAYA Biosciences' Liabilities and Shareholders Equity fell 4.41% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 16.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 73.12% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $1.2 billion for Q3 2025, which was up 13.82% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2024 and a low of $326.1 million during Q1 2021.
  • Over the past 3 years, IDEAYA Biosciences' median Liabilities and Shareholders Equity value was $973.7 million (recorded in 2024), while the average stood at $881.9 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Liabilities and Shareholders Equity soared by 220.36% in 2021 and then fell by 4.41% in 2025.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Liabilities and Shareholders Equity stood at $381.3 million in 2021, then increased by 1.74% to $388.0 million in 2022, then spiked by 67.36% to $649.3 million in 2023, then spiked by 73.12% to $1.1 billion in 2024, then decreased by 4.41% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.2 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.1 billion in Q1 2025.